WO2022234485 - COMPOSITIONS AND METHODS FOR SARS COV-2 RNA DETECTION
National phase entry:
Publication Number
WO/2022/234485
Publication Date
10.11.2022
International Application No.
PCT/IB2022/054128
International Filing Date
04.05.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR SARS COV-2 RNA DETECTION
[French]
COMPOSITIONS ET PROCÉDÉS DE DÉTECTION D'ARN SARS COV-2
Applicants **
KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
Technology Transfer Office
4700 King Abdullah University of Science and Technology
Thuwal, 23955-6900, SA
Inventors
SHUAIB, Muhammad
Technology Transfer Office
4700 King Abdullah University of Science and Technology
Thuwal, 23955-6900, SA
PAIN, Arnab
Technology Transfer Office
4700 King Abdullah University of Science and Technology
Thuwal, 23955-6900, SA
Priority Data
63/183,933
04.05.2021
US
63/333,158
21.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2143 | |
| EPO | Filing, Examination | 13299 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 6110 |
Total: 22750 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Compositions and methods for enriching, isolating, and/or detecting SARS-CoV-2 RNA in a sample are provided. The compositions include the nucleocapsid (N) protein derived from SARS-CoV-2 virus, or a functional fragment or variant thereof, preferably having one or both of R203K and G204R mutations. The compositions are brought in contact with a sample obtained from a subject. The disclosed compositions can be use in methods of detecting SARS-CoV-2 nucleic acids in a sample such as mucus, sputum (processed or unprocessed), bronchial alveolar lavage (BAL), bronchial wash (BW), bodily fluids, cerebrospinal fluid (CSF), urine, tissue (e.g., biopsy material), rectal swab, nasopharyngeal aspirate, nasopharyngeal swab, throat swab, feces, plasma, serum, or whole blood, thus, methods of detecting SARS-CoV-2 in such samples are also provided.[French]
L'invention concerne des compositions et des procédés pour enrichir, isoler et/ou détecter l'ARN du SARS-CoV-2 dans un échantillon. Les compositions comprennent la protéine de nucléocapside (N) dérivée du virus du SARS-CoV-2, ou un fragment fonctionnel ou un variant de celui-ci, de préférence ayant une ou les deux mutations R203K et G204R. Les compositions sont mises en contact avec un échantillon obtenu à partir d'un sujet. Les compositions selon l'invention peuvent être utilisées dans des procédés de détection d'acides nucléiques du SARS-CoV-2 dans un échantillon tel que le mucus, l'expectoration (traitée ou non traitée), le lavage alvéolaire bronchique (BAL), le lavage bronchique (BW), les fluides corporels, le liquide céphalorachidien (CSF), l'urine, les tissus (par exemple, un matériau de biopsie), un écouvillonnage rectal, un aspirat rhinopharyngé, un écouvillonnage nasopharyngé, un prélèvement de la gorge, les selles, le plasma, le sérum ou le sang total, ainsi que, des procédés de détection du SARS-CoV-2 dans de tels échantillons.